The drug, natalizumab (Tysabri), from Biogen Idec is currently in Phase 3b Clinical Trials. Officially titled “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension,” the trial is split into two parts. Part 1 is investigating if natalizumab slows the accumulation of disability not related to relapses relative to a placebo, and Part 2 is a continuation of the safety evaluation of natalizumab, where all participants may receive natalizumab. The trial began in July 2011 and is estimated to be completed in December 2014, with longer-term endpoints being collected for a total of approximately four years.
READ MORE
